Sensus Healthcare: Broadening Horizons of Non-invasive Skin Cancer Treatment
Today nearly 5 million people in the US are treated with skin cancer. With 4 million new cases of non-melanoma skin cancer diagnosed each year. Non-melanoma skin cancer (NMSC) is the fastest growing cancer in the world and is predicted to increase considerably by 2020. Added to that, there are nearly 18 million people affected by keloid scarring.
Sensus Healthcare is dedicated to improving the lives of these people. A medical technology company, Sensus Healthcare is keen on delivering non-invasive and cost-effective treatment for NMSC, keloids, and similar indications to patients all over the world. “Our mission is to offer a wide range of aesthetic and clinical solutions to patients, not only to treat skin cancer but also to help people look and feel their best from head to toe,” says Joe Sardano, CEO, Chairman, and Co-Founder of Sensus Healthcare.
Sensus Healthcare utilizes their proprietary, reliable and high-end Superficial Radiation Therapy technology (SRT)—SRT 100—to safely treat oncological and non-oncological skin conditions. SRT is a low-energy photon radiotherapy that can be specifically focused on cancer cells, penetrating no more than 5 mm under the surface of the skin, thus sparing the healthy tissues nearby. It is an ideal choice for NMSC patients over the age of 60, where medical conditions such as diabetes and cardiac diseases make surgical treatments a serious health risk. Low-dose SRT effectively cures basal cell carcinoma and squamous cell carcinoma without any cutting, bleeding, or stitching. SRT-100 nullifies the need for anesthesia, the risk of infection or scarring, and reconstructive plastic surgery.
In their continuous attempt to innovate the treatment of non-melanoma skin cancer and unsightly keloid scarring, Sensus Healthcare offers the SRT-100 Vision, an upgraded, next-generation version of SRT-100. Along with all the remarkable features of its prototype, the SRT-100 Vision features a high-frequency ultra-sound guidance system, which allows physicians to assess treatment areas in real-time and fine tune the required amount of radiation. This compact, portable and efficient technology can enhance the rate of patient treatment, enabling the physicians to increase their patient intake and also help personalize individual patient treatments. Furthermore, the non-surgical SRT-100 Vision technology delivers over 95 percent cure rate for non-melanoma cancer and over 94 percent cure rate for keloid scarring, lowering the overall cost of healthcare. SRT-100 Vision technology also features Vision laser positioning system, Vision lesioncam, Vision touch-screen control console, and control module, and more to further assist the physicians in their work.
Sensus Healthcare is dedicated to improving the lives of these people. A medical technology company, Sensus Healthcare is keen on delivering non-invasive and cost-effective treatment for NMSC, keloids, and similar indications to patients all over the world. “Our mission is to offer a wide range of aesthetic and clinical solutions to patients, not only to treat skin cancer but also to help people look and feel their best from head to toe,” says Joe Sardano, CEO, Chairman, and Co-Founder of Sensus Healthcare.
Sensus Healthcare utilizes their proprietary, reliable and high-end Superficial Radiation Therapy technology (SRT)—SRT 100—to safely treat oncological and non-oncological skin conditions. SRT is a low-energy photon radiotherapy that can be specifically focused on cancer cells, penetrating no more than 5 mm under the surface of the skin, thus sparing the healthy tissues nearby. It is an ideal choice for NMSC patients over the age of 60, where medical conditions such as diabetes and cardiac diseases make surgical treatments a serious health risk. Low-dose SRT effectively cures basal cell carcinoma and squamous cell carcinoma without any cutting, bleeding, or stitching. SRT-100 nullifies the need for anesthesia, the risk of infection or scarring, and reconstructive plastic surgery.
In their continuous attempt to innovate the treatment of non-melanoma skin cancer and unsightly keloid scarring, Sensus Healthcare offers the SRT-100 Vision, an upgraded, next-generation version of SRT-100. Along with all the remarkable features of its prototype, the SRT-100 Vision features a high-frequency ultra-sound guidance system, which allows physicians to assess treatment areas in real-time and fine tune the required amount of radiation. This compact, portable and efficient technology can enhance the rate of patient treatment, enabling the physicians to increase their patient intake and also help personalize individual patient treatments. Furthermore, the non-surgical SRT-100 Vision technology delivers over 95 percent cure rate for non-melanoma cancer and over 94 percent cure rate for keloid scarring, lowering the overall cost of healthcare. SRT-100 Vision technology also features Vision laser positioning system, Vision lesioncam, Vision touch-screen control console, and control module, and more to further assist the physicians in their work.
Nearly 80 percent of all skin cancer occurs on delicate areas of the head and neck along the fold of the nose, eyelids, lips, corner of the mouth and the lining of the ear, and Sensus Healthcare’s portable SRT technology is well equipped to address these issues. It is an effective alternative to the traditional Mohs surgery, which involves invasive cutting through healthy tissue, painful healing, lengthy recovery, and unsightly scarring. With SRT technology, patients undergoing NMAC treatment don’t have to worry about disfigurement, nerve damage, painful recovery or muscle injury. Sensus Healthcare recently launched Sensus Laser Systems, a multi-platform line of high-quality, cost-effective dermatological lasers, which capacitates cutting-edge solutions for hair and tattoo removal, acne lesion correction, skin rejuvenation, and pigmentation/large pore treatment.
Our mission is to offer a wide range of aesthetic and clinical solutions to patients, not only to treat skin cancer but also to help people look and feel their best from head to toe
Sensus Healthcare has established itself in China and Israel, and looks forward to expanding their business to India and other Asian Countries. They also aim to build strategic partnerships with other companies, physicians, and organizations, to create awareness on the importance of non-invasive cancer treatment and to leverage innovations in their product line.
